Viridian Therapeutics Prepares for Transformational 2026
Stocks in this Quantisnow insightHealth Care
Historical context for VRDN
Across the 10 sessions after earlier VRDN headlines, the stock closed higher 5 times and lower 5 times, with a median move of 2.3% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VRDN | SPY |
|---|---|---|---|
| Dec 22, 2025 | Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease | +1.7% | +0.6% |
| Dec 10, 2025 | Wedbush reiterated coverage on Viridian Therapeutics with a new price target | +2.5% | +0.7% |
| Dec 5, 2025 | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -1.4% | +0.2% |
| Dec 3, 2025 | William Blair initiated coverage on Viridian Therapeutics | +2.9% | +0.3% |
| Nov 24, 2025 | Truist initiated coverage on Viridian Therapeutics | +5.6% | +1.5% |
| Nov 7, 2025 | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -0.2% | +0.1% |
Keep researching VRDN
- VRDN insider tradesEvery buy and sale reported by Viridian Therapeutics Inc. officers, directors and large holders.
- VRDN earnings historyPast Viridian Therapeutics Inc. earnings releases, newest first.
- VRDN financial statementsRevenue, profit, cash flow and balance sheet from Viridian Therapeutics Inc.'s SEC filings.
Quantisnow market dataNASDAQ
VRDN
Viridian Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for VRDN
Full VRDN profile on Quantisnow Follow VRDN and get a push notification the moment its next story breaks.